# Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

> **NCT03591874** · PHASE3 · TERMINATED · sponsor: **Ocugen** · enrollment: 59 (actual)

## Conditions studied

- Graft Versus Host Disease
- Ocular Surface Disease
- oGVHD
- Ocular Graft vs Host Disease
- Brimonidine Tartrate
- Lubricant Eye Drops
- Ophthalmic Solutions
- Graft vs Host Disease

## Interventions

- **DRUG:** Brimonidine Tartrate
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03591874
- **Lead sponsor:** Ocugen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-23
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Primary endpoint was not met.
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591874, "Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03591874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*